Graphite’s hopes for sickle cell ‘cure’ blunted after first patient dosed experiences serious event

Graphite Bio has cited a “serious adverse event in the first patient dosed” with its gene therapy nulabeglogene autogedtemcel (nula-cel) and paused its lead program.